46.4% on Rinvoq hit sustained remission vs. 29.0% on placebo in Phase 3 giant cell arteritis trial. Rinvoq Q1 sales hit $1.72 billion, rising 57.2% year-over-year. Don’t miss this list of 10 ...

AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib ... and the biggest-selling drug in the world. For comparison, treatment of RA with Humira – which requires regular ...

AbbVie has won expanded European approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis. AbbVie on Tuesday said the European Commission's nod ...

Rinvoq's guidance was raised by $300 million to $8.2 billion, driven by growth across rheumatology, dermatology, and IBD. U.S. Humira revenue guidance was lowered by $500 million to $3.5 billion ...

NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib), 15 mg, once daily ...

(RTTNews) - AbbVie (ABBV) Tuesday said the U.S. Food and Drug Administration (FDA) has approved Rinvoq for the treatment of adults with giant cell arteritis (GCA). GCA is an autoimmune disease ...

The European Commission (“EC”) granted marketing approval to AbbVie’s Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes inflammation of the large arteries.